Old Web
English
Sign In
Acemap
>
authorDetail
>
Sivakumar Vaidyanathan
Sivakumar Vaidyanathan
Biocon
ARDS
Medicine
Itolizumab
Internal medicine
Coronavirus disease 2019
3
Papers
8
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV Itolizumab Trial: RESURRECT
2021
medRxiv
KR Raveendra
Chirag Rathod
Rahul Darnule
Subramanian Loganathan
Sarika Deodhar
A Radhika
Ashwani Marwah
Nitin M Chaudhari
Binay K Thakur
Sivakumar Vaidyanathan
Sandeep N. Athalye
Show All
Source
Cite
Save
Citations (0)
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
2021
Expert Opinion on Biological Therapy
Suresh Kumar
Rosemarie de' Souza
Milind Y Nadkar
Randeep Guleria
Anjan Trikha
Shashank R. Joshi
Subramanian Loganathan
Sivakumar Vaidyanathan
Ashwani Marwah
Sandeep N. Athalye
Show All
Source
Cite
Save
Citations (6)
A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
2020
medRxiv
Suresh Kumar
Rosemarie de' Souza
Milind Y Nadkar
Randeep Guleria
Anjan Trikha
Shashank R. Joshi
Subramanian Loganathan
Sivakumar Vaidyanathan
Ashwani Marwah
Sandeep N. Athalye
Show All
Source
Cite
Save
Citations (2)
1